|
|
|
|
LEADER |
04756nam a2200985Ia 4500 |
001 |
10.1002-jcla.23617 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a Dysregulation of vitamin D synthesis pathway genes in colorectal cancer: A case-control study
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23617
|
520 |
3 |
|
|a Background: The cytochromes P450 are a superfamily of enzymes that control the synthesis of the biologically active form of vitamin D, 1,25-dihydroxyvitamin D3. These enzymes contribute to the formation of 1,25-dihydroxyvitamin D3, which starts with a 25-hydroxylation by CYP2R1 and CYP27A1 and a subsequent 1α-hydroxylation via CYP27B1. Methods: By using quantitative real-time polymerase chain reaction (qRT-PCR), we analyzed the expression ratio of CYP2R1, CYP27A1 and CYP27B1 genes within the vitamin D metabolic pathway in a total of 75 colorectal cancer (CRC) tissues compared to the adjacent tissues. Furthermore, we evaluated the association of CYP27B1 rs4646536 and CYP2R1 rs12794714 and rs10766196 polymorphisms with CRC risk in a total of 490 subjects, including 245 CRC patients and 245 non-cancer controls. The genotyping was performed using tetra-primer amplification refractory mutation system polymerase chain reaction (TP-ARMS–PCR) method. Results: The results indicated 2.3 and 2.7 upregulation of CYP2R1 and CYP27B1 genes in colorectal cancer tissues compared to the adjacent tissues, respectively. Rs12794714 AG genotype increased the risk of CRC (P =.03). Furthermore, a significant association was observed under the dominant inheritance model (P =.039). Conclusion: CYP2R1 and CYP27B1 genes were over-expressed in CRC samples compared to the adjacent control tissues. Furthermore, CYP2R1 rs12794714 variant was associated with the risk of CRC in the studied samples. CYP2R1 rs10766196 and CYP27B1 rs4646536 are not responsible for CYP2R1 and CYP27B1 genes expression alteration, respectively, but CYP2R1 rs12794714 polymorphism may be the reason of CYP2R1 upregulation and increased the risk of CRC. © 2020 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
|
650 |
0 |
4 |
|a 25-Hydroxyvitamin D3 1-alpha-Hydroxylase
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a aged
|
650 |
0 |
4 |
|a Aged
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a biosynthesis
|
650 |
0 |
4 |
|a calcidiol 1 monooxygenase
|
650 |
0 |
4 |
|a case control study
|
650 |
0 |
4 |
|a Case-Control Studies
|
650 |
0 |
4 |
|a cholestanetriol 26 monooxygenase
|
650 |
0 |
4 |
|a cholestanetriol 26 monooxygenase
|
650 |
0 |
4 |
|a Cholestanetriol 26-Monooxygenase
|
650 |
0 |
4 |
|a colorectal cancer
|
650 |
0 |
4 |
|a colorectal cancer
|
650 |
0 |
4 |
|a Colorectal Neoplasms
|
650 |
0 |
4 |
|a colorectal tumor
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a CYP27A1 gene
|
650 |
0 |
4 |
|a CYP27A1 protein, human
|
650 |
0 |
4 |
|a CYP27B1
|
650 |
0 |
4 |
|a CYP27B1 gene
|
650 |
0 |
4 |
|a CYP27B1 protein, human
|
650 |
0 |
4 |
|a CYP2R1
|
650 |
0 |
4 |
|a CYP2R1 gene
|
650 |
0 |
4 |
|a CYP2R1 protein, human
|
650 |
0 |
4 |
|a cytochrome P450 family 2
|
650 |
0 |
4 |
|a Cytochrome P450 Family 2
|
650 |
0 |
4 |
|a DNA extraction
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a gene
|
650 |
0 |
4 |
|a gene expression
|
650 |
0 |
4 |
|a gene expression regulation
|
650 |
0 |
4 |
|a Gene Expression Regulation, Neoplastic
|
650 |
0 |
4 |
|a gene frequency
|
650 |
0 |
4 |
|a Gene Frequency
|
650 |
0 |
4 |
|a genetic association
|
650 |
0 |
4 |
|a genetic risk
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a genotype
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a human tissue
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a Iranian people
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a Middle Aged
|
650 |
0 |
4 |
|a pathology
|
650 |
0 |
4 |
|a Polymorphism, Single Nucleotide
|
650 |
0 |
4 |
|a population research
|
650 |
0 |
4 |
|a real time polymerase chain reaction
|
650 |
0 |
4 |
|a single nucleotide polymorphism
|
650 |
0 |
4 |
|a single-nucleotide polymorphism
|
650 |
0 |
4 |
|a tetra primer amplification refractory mutation system polymerase chain reaction
|
650 |
0 |
4 |
|a upregulation
|
650 |
0 |
4 |
|a vitamin D
|
650 |
0 |
4 |
|a vitamin D
|
650 |
0 |
4 |
|a vitamin D
|
650 |
0 |
4 |
|a Vitamin D
|
700 |
1 |
|
|a Aghaei, N.
|e author
|
700 |
1 |
|
|a Asadzadeh Aghdaei, H.
|e author
|
700 |
1 |
|
|a Kamaliyan, Z.
|e author
|
700 |
1 |
|
|a Mirfakhraie, R.
|e author
|
700 |
1 |
|
|a Mohseni, R.
|e author
|
700 |
1 |
|
|a Moshiri, A.
|e author
|
700 |
1 |
|
|a Nazemalhosseini-Mojarad, E.
|e author
|
700 |
1 |
|
|a Sadeghi, H.
|e author
|
700 |
1 |
|
|a Sahebi, U.
|e author
|
700 |
1 |
|
|a Zali, M.R.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|